Review of KEYNOTE-426: Five-year Follow-up Data

Opinion
Video

The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.

  1. Dr McKay: Please briefly review key efficacy and safety data from the KEYNOTE-426 trial 5-year final analysis (Plimack et al. Eur Urol. 2023)?
    • What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
    • In responders, how important is the durability of the response (OS and PFS) for both the intermediate/poor and favorable-risk groups?

Related Videos
Martin H. Voss, MD, an expert on kidney cancer
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Martin H. Voss, MD, an expert on kidney cancer
Related Content